Live Breaking News & Updates on Takeda Development Center Americas|Page 2

Stay updated with breaking news from Takeda development center americas. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

New Biomarker Tests Could Reduce Need for Liver Biopsy

New biomarker tests identified NASH and related conditions at least as well as common lab tests, paving the way for blood-based alternatives to liver biopsy for clinical care and therapeutic trials. ....

United States , New York , Tatyana Kushner , Tarun Sanyal , Ge Healthcare , Intercept Pharmaceuticals , Translational Sciences , National Institute Of Diabetes , Drug Administration , Division Of Liver Diseases , Icahn School Of Medicine At Mount Sinai , Global Liver Institute , Novo Nordisk , Foundation For The National Institutes Of Health , Regeneron Pharmaceuticals , National Center , Boehringer Ingelheim , Gilead Sciences , Takeda Development Center Americas , Clinical Research Network , Bristol Myers Squibb , Stravitz Sanyal Institute For Liver Disease , Metabolic Health At Virginia Commonwealth University , Stravitz Sanyal Institute , Liver Disease , Metabolic Health ,

Lanadelumab Shown to Significantly Reduce Hereditary Angioedema Attacks in Japanese Patients

This new data is consistent with previous results on efficacy and on safety shown in global phase 3 studies that had enrolled both adults and adolescents.
....

United States , Ming Yu , Takeda Pharmaceutical Company , Takeda Development Center Americas Inc , Takeda Development Center Americas , Pharmaceutical Company ,

Orexin Receptor 2 Agonist Improves Sleepiness in Narcolepsy

For patients with narcolepsy type 1, an orexin receptor 2 agonist, TAK-994, improves measures of sleepiness and cataplexy. ....

Yves Dauvilliers , University Of Montpellier , Takeda Development Center Americas , Healthday News , New England Journal , Gui De Chauliac Hospital , Wakefulness Test , Epworth Sleepiness Scale , Takeda Development Center ,

Orexin Receptor 2 Agonist Improves Sleepiness in Narcolepsy

For patients with narcolepsy type 1, TAK-994 improves measures of sleepiness and cataplexy over 8 weeks compared with placebo. ....

Yves Dauvilliers , University Of Montpellier , Takeda Development Center Americas , Healthday News , New England Journal , Gui De Chauliac Hospital , Wakefulness Test , Epworth Sleepiness Scale , Takeda Development Center ,

Orexin Receptor 2 Agonist Improves Sleepiness in Narcolepsy

Improvement seen in measures of sleepiness, cataplexy over eight weeks versus placebo, but drug was associated with hepatotoxic effects. ....

Yves Dauvilliers , University Of Montpellier , Takeda Development Center Americas , Healthday News , New England Journal , Gui De Chauliac Hospital , Wakefulness Test , Epworth Sleepiness Scale , Takeda Development Center ,